Arbutus Biopharma Corp (ABUS) Total liabilities 2016–2025
Arbutus Biopharma Corp (ABUS) total liabilities at each fiscal year-end, per SEC filings.
$18.0MFY2025 · since FY2016: $72.9M → $18.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $18.0M | -47.5% |
| FY2024 | $34.3M | -10.5% |
| FY2023 | $38.4M | -34.5% |
| FY2022 | $58.6M | +67.1% |
| FY2021 | $35.0M | -0.2% |
| FY2020 | $35.1M | +7.1% |
| FY2019 | $32.8M | +18.5% |
| FY2018 | $27.7M | -49.4% |
| FY2017 | $54.7M | -25.0% |
| FY2016 | $72.9M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice